Home » Stocks » CALT

Calliditas Therapeutics AB (CALT)

Stock Price: $26.88 USD -0.31 (-1.14%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 675.66M
Revenue (ttm) 19.87M
Net Income (ttm) -3.50M
Shares Out 24.97M
EPS (ttm) -0.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $26.88
Previous Close $27.19
Change ($) -0.31
Change (%) -1.14%
Day's Open 27.19
Day's Range 26.80 - 27.25
Day's Volume 14,993
52-Week Range 19.00 - 38.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Calliditas Therapeutics (NASDAQ: CALT) has submitted a marketing application to the FDA seeking approval for Nefecon, an oral formulation targeting down-regulation of IgA1 for primary IgA Nephropathy (I...

1 month ago - Benzinga

STOCKHOLM, Feb. 18, 2021 /PRNewswire/ -- "On November 8, 2020, we announced positive topline readout of Part A of our Phase 3 pivotal trial, NefIgArd. The results were statistically significant and clin...

2 months ago - PRNewsWire

Calliditas Therapeutics AB (NASDAQ: CALT) has dosed that first patient in the global open-label extension part of Phase 3 study (dubbed as NefIgArd) that will offer a 9-month treatment with Nefecon to a...

2 months ago - Benzinga

Undervalued stocks that are likely to surge higher in the next few quarters supported by company specific catalysts and industry tailwinds. The post 4 Undervalued Stocks That Could Rip Higher appeared f...

Other stocks mentioned: LMT, SNDL, SOLO
2 months ago - InvestorPlace

STOCKHOLM, Jan. 26, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (Nasdaq: CALT) will today launch a proposed public offering of American Depositary Shares ("...

2 months ago - PRNewsWire

STOCKHOLM, Jan. 21, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX: CALTX) (NASDAQ: CALT) today announced that all 360 patients have been enrolled for the global Phase...

2 months ago - PRNewsWire

STOCKHOLM, Nov. 27, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ.) publishes the nomination committee's composition for the AGM in 2021. The nomination committee, which is appointed in accordan...

4 months ago - PRNewsWire

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstratio...

Other stocks mentioned: BGNE, BNTX, IMAB, MRK, PFE, TMO
5 months ago - Seeking Alpha

STOCKHOLM, Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the third quarter 2020. Calliditas will also h...

5 months ago - PRNewsWire

STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- On November 8, 2020, Calliditas announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nef...

5 months ago - PRNewsWire

STOCKHOLM, Nov. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (OMX Nasdaq: CALTX) (NASDAQ: CALT) ("Calliditas") today announced positive topline results from Part A of the global Phase 3 clinical t...

5 months ago - PRNewsWire

STOCKHOLM, Sept. 30, 2020 /PRNewswire/ -- During September, Calliditas Therapeutics AB (publ) has allotted 111,250 common shares within the company's warrant program issued in 2017. Thus, as of Septembe...

6 months ago - PRNewsWire

Successful capital raise on NASDAQ STOCKHOLM, Aug. 13, 2020 /PRNewswire/ -- "In June we successfully closed a $90m U.S.

8 months ago - PRNewsWire

STOCKHOLM, Aug. 11, 2020 /PRNewswire/ -- On August 13, 2020, at 07:00 am CET, Calliditas Therapeutics ("Calliditas") will publish its business update for the second quarter 2020.

8 months ago - PRNewsWire

Calliditas Therapeutics (NASDAQ: CALT) shares are trading higher on Tuesday after Jefferies initiated coverage on the stock with a Buy rating and a price target of $44 per share.

9 months ago - Benzinga

About CALT

Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephro... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jun 5, 2020
Stock Exchange
NASDAQ
Ticker Symbol
CALT
Full Company Profile

Financial Performance

Financial numbers in millions SEK.
Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for CALT stock is "Strong Buy." The 12-month stock price forecast is 49.60, which is an increase of 84.52% from the latest price.

Price Target
$49.60
(84.52% upside)
Analyst Consensus: Strong Buy